Gene therapy offers a powerful tool for treating or curing debilitating diseases that have vexed medical science for years.

Patients battling conditions like hemophilia B, sickle cell anemia, beta thalassemia, Duchenne muscular dystrophy and other ailments now have new options to consider in their treatment plans.

But let's be blunt. Gene therapy is also... at least for now... really, REALLY expensive.

And so, as these incredible treatments and technologies are unveiled, those of us in the stop loss and reinsurance industries have to stay informed about new developments in gene therapy, the implications of insurance for gene therapy, and the greater economic and social forces in play.

To help us explore these topics, we're bringing in expertise from Ashley Hume, President of Emerging Therapy Solutions; Brooks Wildasin, Chief Product and Innovation Officer at Havarti Risk; and Kelly Munger, Head of US Health at PartnerRe. 

🖥️ Play on BCS website – https://bcsf.com/firmandfinalpodcast/
🎧 Listen on Spotify – https://spoti.fi/3U7rYuq
🍎 Listen on Apple Podcasts – https://apple.co/3Kvdlhg
☑️ Sign up to subscribe – https://bcsf.com/firmandfinalpodcast/
🦸 Recommend a Legend – [email protected]